FDA approves Roivant drug, the first novel topical plaque psoriasis med in 25 years

FDA approves Roivant drug, the first novel topical plaque psoriasis med in 25 years

Source: 
MedCity News
snippet: 

Plaque psoriasis drug Vtama is now approved by the FDA, making it the first novel topical treatment for the chronic autoimmune disorder in a generation. Roivant Sciences subsidiary Dermavant Sciences acquired the drug from GlaxoSmithKline in 2018.